Publications
Specialty
Search
Journal of Clinical Pathways
06/26/2024
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care resource utilization.
IO Learning
06/26/2024
In this commentary, Charles Martin, MD, discusses the advancing of imaging technologies and how interventional radiologists may be able to use AR to assist in their treatment.
Oncology, Journal of Clinical Pathways, Lymphoma, Leukemia & Myeloma Network
06/26/2024
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with bendamustine for patients with R/R chronic lymphocytic leukemia.
Oncology
06/25/2024
Aaron Gerds, MD, discusses data from the MANIFEST-2 and TRANSFORM-1 trials exploring first-line treatment options for patients with myelofibrosis, as well as analyzes the establishment of optimal clinical trial end points.
EP Lab Digest
06/25/2024
ALBUQUERQUE, N.M. -- Today Heart Hospital of New Mexico at Lovelace Medical Center (HHNM) and GE HealthCare (Nasdaq: GEHC) announced HHNM as the first location in the United States to install GE HealthCare’s latest Allia Image Guided System (IGS) Pulse, which was designed to provide exceptional image quality and improve workflow for the diagnosis and treatment of cardiovascular diseases (CVD).
EP Lab Digest
06/25/2024
AliveCor, the global leader in AI-powered cardiology, today announced the U.S. Food and Drug Administration (FDA) clearance and commercial launch of KAI™ 12L AI technology and the Kardia™ 12L ECG System. This is the world’s first AI that can detect life-threatening cardiac conditions, including heart attacks, using a reduced leadset. The Kardia 12L ECG System, featuring a game-changing patented technology, is the world’s first AI-powered, handheld 12-lead electrocardiogram (ECG) system with a unique single-cable design.
Psych Congress Network
06/25/2024
An investigational, once-monthly, subcutaneous long-acting injection of olanzapine called TEV-‘749 met its primary endpoint in the efficacy portion of the phase 3 SOLARIS trial.
EMSWorld
06/25/2024
The council heard from experts on topics ranging from microscopic—the nation’s response to emerging infectious pathogens—to beyond that when they learned about preparations for medical care for astronauts traveling to Mars.
Psych Congress Network, Neurology, Psychiatry & Behavioral Health
06/25/2024
Exploratory outcomes from a phase 2a trial suggest that the first-in-class small molecule LM11A-31 slowed progression of pathophysiological features of mild to moderate Alzheimer disease (AD) over 26 weeks.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
06/25/2024
Despite receiving approval, international guidelines still recommend open surgical replacement in populations with bicuspid aortic valve (BAV) disease. As a result, TAVR treatment for BAVs still remains relatively low in comparison to transcatheter aortic valve replacement treatment for tricuspid aortic valves.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
06/25/2024
“The successful management of hypertension depends on patients being able to take blood pressure measurements easily and reliably outside of the traditional doctor’s office setting,” said corresponding author Naomi Fisher, MD. “Cuffless devices have the potential to revolutionize hypertension management. They provide many more readings than traditional devices, during both the day and night, which can help confirm the diagnosis of hypertension and guide medication titration.”
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
06/25/2024
A weekly dose of semaglutide 2.4 mg significantly reduced the risk of major adverse cardiovascular events (MACEs) in people with overweight or obesity and cardiovascular disease but not diabetes, regardless of blood sugar level, according to a clinical trial including researchers from UT Southwestern Medical Center.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
06/25/2024
Alnylam Pharmaceuticals, Inc., an RNAi therapeutics company, announced positive topline results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM).
Vascular Disease Management, CardioVascular
06/25/2024
At the 2024 SIR Meeting, Waseem Wahood, MD, MS presented results from a study that analyzed 30-day perioperative outcomes from the National Surgical Quality Improvement Project in patients who received intervention for CLTI.
Podiatry Today
06/25/2024
Dr. Kirby spoke to Podiatry Today about his session at the Western Foot and Ankle Conference.
Psych Congress Network, Neurology
06/25/2024
Attention-deficit/hyperactivity disorder (ADHD) was associated with an increased risk of Lewy Body disease (LBD), according to results from a recent prospective observational cohort study published in The American Journal of Geriatric Psychiatry.
Oncology
06/25/2024
According to data from the 2024 EHA Congress, long-term results of the phase 3 SIERRA trial demonstrated that conditioning and induction with 131I-apamistamab (Iomab-B) was well-tolerated and allowed for access to HCT with curative potential for older patients with R/R acute myeloid leukemia.
Wounds, Wound Care
06/25/2024
© 2024 HMP Global.
The Dermatologist
06/25/2024
Topical roflumilast has demonstrated robust local tolerability profiles in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis.
Advances in Inflammatory Bowel Disease Network
06/25/2024
Dr Holubar presented at Digestive Disease Week the results of a study on patient-reported outcomes before and after for IBD to determine if surgery delivers on its promises to improve quality of life for patients with IBD.